Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review

(2022) Neha Potla et al.   International Journal of Emergency Medicine

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

(2022) Christopher Elnan Kvistad et al.   LANCET NEUROLOGY

Statistical analysis plan for the randomized controlled trial Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)

(2022) Agnethe Eltoft et al.   Trials

Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial

(2022) Urs Fischer et al.   LANCET

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

(2022) Bijoy K Menon et al.   LANCET

Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial

(2022) Peter J Mitchell et al.   LANCET

Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial

(2021) Melinda B Roaldsen et al.   International Journal of Stroke

Thrombolytic therapy for wake‐up stroke: A systematic review and meta‐analysis

(2021) Brian Mac Grory et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

(2020) Bruce C. V. Campbell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Safety of Thrombolytic Therapy for Stroke with Unknown Time of Onset: A Meta-Analysis of Observational Studies

(2020) Ruo-lin Zhu et al.   Journal of Stroke & Cerebrovascular Diseases

Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset

(2020) Masatoshi Koga et al.   STROKE

Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

(2019) Ewgenia Barow et al.   JAMA Neurology

Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection

(2019) Peter Ringleb et al.   International Journal of Stroke

Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

(2019) Henry Ma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke

(2019) Adrian M. Burgos et al.   STROKE

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

(2018) Götz Thomalla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms

(2018) Victor C. Urrutia et al.   PLoS One

Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials

(2018) Shelagh B Coutts et al.   International Journal of Stroke

Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke

(2016) Andrew D. Barreto et al.   ANNALS OF NEUROLOGY

Association Between Time From Stroke Onset and Fluid-Attenuated Inversion Recovery Lesion Intensity Is Modified by Status of Collateral Circulation

(2016) Anke Wouters et al.   STROKE

The Heidelberg Bleeding Classification

(2015) Rüdiger von Kummer et al.   STROKE

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

(2014) Jonathan Emberson et al.   LANCET

Wake-Up Stroke and Stroke of Unknown Onset: A Critical Review

(2014) Anke Wouters et al.   Frontiers in Neurology

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

(2012)   LANCET

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

(2012) Joanna M Wardlaw et al.   LANCET

DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study

(2011) Götz Thomalla et al.   LANCET NEUROLOGY